Applied Therapeutics (APLT, Financial) is set to present at the Peripheral Nerve Society's 2025 Annual Meeting, scheduled from May 17-20. The focal point of the presentation will be the full 12-month clinical outcomes from their INSPIRE Phase 3 trial of govorestat, also known as AT-007, aimed at treating SORD Deficiency, a subtype of Charcot-Marie-Tooth disease. Additionally, the event will highlight new topline data from 18 and 24-month periods. This follows their release of initial 12-month results back in February 2024.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Applied Therapeutics Inc (APLT, Financial) is $2.88 with a high estimate of $5.00 and a low estimate of $1.50. The average target implies an upside of 619.29% from the current price of $0.40. More detailed estimate data can be found on the Applied Therapeutics Inc (APLT) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, Applied Therapeutics Inc's (APLT, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
